Skip to main content
UniHealth

Doctor search

Reetesh K Pai, MD

Pathology · Johnstown

NPI 1962608364

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2

Offices

2 locations · University of Pittsburgh Physicians · 4,166 clinicians in this group

Looking this up.

Hospitals listed: Magee Womens Hospital of Upmc Health System · Upmc Presbyterian Shadyside. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Pai’s office at (814) 533-0134 to ask if they take your plan before you enroll.

California Medical Board record

Licence A89127 · Cancelled

Licence status: Cancelled · since 2004 · University of New Mexico School of Medicine.

License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Magee Womens Hospital of Upmc Health SystemPittsburgh, PAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of UPMC, which runs 34 hospitals in 3 statesPatients rate it 3 of 5 · 78% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.464, Oct 2024 – Sep 2025
  • Upmc Presbyterian ShadysidePittsburgh, PAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of UPMC, which runs 34 hospitals in 3 statesHome of UPMC Hillman Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.4 (1.22 to 1.57), Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.84 (1.45 to 2.22) · 11,546 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.481, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.755, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.597, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.355, Oct 2024 – Sep 2025
See every measure and the patient survey for Magee Womens Hospital of Upmc Health System

Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 8 the same, 0 worse of 8 measures. Readmissions: 1 better, 6 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Magee Womens Hospital of Upmc Health System
Clostridium Difficile (C.Diff)Infections0.464BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.88 (0 to 1.88) · 437 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.21 (0.79 to 1.63)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths172.15 (110.62 to 233.69) · 25 casesNo differentJul 2022 – Jun 2024
Death rate for heart failure patientsComplications and deaths11.1 · 36 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths15.6 · 33 casesNoneJul 2022 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.6 · 859 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.43) · 1,432 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.25 (0.04 to 0.46) · 1,498 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.85 (1.55 to 6.16) · 569 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths2.03 (0.34 to 3.71) · 378 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.62 (1 to 4.24) · 563 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.49 (0.02 to 16.96) · 392 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.96 (1.99 to 9.93) · 362 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.69 (0.19 to 3.18) · 158 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths1.28 (0.24 to 2.33) · 1,064 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.3 · 274 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.246No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.593No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.525No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections1.145No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.39No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21 · 142 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-11 · 43 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-42.1 · 34 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.6 · 134 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.7 (3.9 to 5.5) · 2,366 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11.7 (10.5 to 13.1) · 2,366 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits4.9 · 229 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits18.4 · 87 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.1 (9.1 to 16.1) · 736 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.3) · 585 casesNo differentJan 2024 – Dec 2024

What patients said (368 patients answered, 13% of those asked)

Patient survey stars by topic at Magee Womens Hospital of Upmc Health System
Cleanliness4
Nurse communication4
Doctor communication3
Communication about medicines2
Discharge information4
Overall hospital rating3
Quietness3
Recommend hospital4
Share of patients giving the best answer at Magee Womens Hospital of Upmc Health System
Room was "always" clean74%
Nurses "always" communicated well82%
Doctors "always" communicated well77%
Staff "always" explained58%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand73%
Doctors "always" listened carefully74%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)73%
Staff "always" explained new medications71%
Nurses "always" explained things so they could understand76%
Nurses "always" listened carefully81%
Nurses "always" treated them with courtesy and respect89%
"Always" quiet at night55%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects45%
Yes, staff "did" give patients information about possible symptoms88%
See every measure and the patient survey for Upmc Presbyterian Shadyside

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 3 better, 3 the same, 1 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Upmc Presbyterian Shadyside
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.4 (1.22 to 1.57)WorseJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths1.84 (1.45 to 2.22) · 11,546 casesWorseJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.481BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.755BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.597BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.355BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.9 (0.25 to 1.55) · 4,065 casesNo differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths167.94 (137.62 to 198.26) · 391 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.6 · 136 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11 · 156 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths7.6 · 423 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths12 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 718 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.6 · 8,785 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.05 to 0.39) · 13,123 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.39 (0.23 to 0.56) · 14,320 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.15 (1.9 to 4.41) · 4,999 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.71 (0.65 to 2.78) · 2,630 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.3 (1.31 to 3.29) · 4,417 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.58 (7.41 to 13.74) · 2,469 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.69 (3.73 to 7.65) · 2,617 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.84 (0.67 to 3.01) · 1,552 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.6 · 387 casesNoneApr 2023 – Mar 2025
MRSA BacteremiaInfections0.86No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.2 · 664 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits23.1 · 1,405 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-2.8 · 212 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-16.5 · 523 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits27.7 · 425 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits19.7 · 1,228 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.6 (3.1 to 6.8) · 213 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits8.1 (5.9 to 10.8) · 213 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits4.6 · 383 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits13.7 · 262 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.1 · 439 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits11.2 (8.8 to 14.2) · 2,561 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.3) · 1,016 casesNo differentJan 2024 – Dec 2024

What patients said (612 patients answered, 26% of those asked)

Patient survey stars by topic at Upmc Presbyterian Shadyside
Cleanliness3
Nurse communication4
Doctor communication3
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Upmc Presbyterian Shadyside
Room was "always" clean65%
Nurses "always" communicated well80%
Doctors "always" communicated well78%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand72%
Doctors "always" listened carefully76%
Doctors "always" treated them with courtesy and respect85%
Patients who gave a rating of "9" or "10" (high)71%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand76%
Nurses "always" listened carefully77%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night47%
"YES", patients would definitely recommend the hospital72%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$36,530

Medicare paid this office $36,530 for 376 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Pathology examination of tissue using a microscope, intermediate complexity302$15,408$25
Special stained specimen slides to examine tissue, each additional procedure67$7,465$20
Special stained specimen slides to examine tissue, initial procedure110$3,628$26
Pathology examination of tissue using a microscope, high complexity15$2,977$106
Pathology examination of tissue using a microscope, moderately high complexity24$2,032$55
See all 10 services
Every Original Medicare service billed
Pathology examination of tissue using a microscope, intermediate complexity302$15,408$25
Special stained specimen slides to examine tissue, each additional procedure67$7,465$20
Special stained specimen slides to examine tissue, initial procedure110$3,628$26
Pathology examination of tissue using a microscope, high complexity15$2,977$106
Pathology examination of tissue using a microscope, moderately high complexity24$2,032$55
Microscopic genetic analysis of tumor, manual29$1,407$31
Surgical pathology consultation and report on referred material requiring preparation of slides12$783$65
Special stained specimen slides to identify organisms including interpretation and report13$275$20
Special stained specimen slides to examine tissue including interpretation and report13$258$9
Pathology examination of tissue using a microscope, moderately low complexity21$219$8

Who their Medicare patients are

376 Original Medicare patients in 2024. Average age 71 · Under 65 10% · 85 and older 4% · Women 53% · Also on Medicaid 10% · Health risk score 1.31. At or below the middle of the specialty; the typical pathology clinician is at 1.55.

Conditions among them: High blood pressure 70% · Coronary heart disease 30% · Depression 30% · Diabetes 28% · Cancer 27% · Chronic kidney disease 18% · COPD 16% · Atrial fibrillation 15% · Heart failure 13% · Stroke 11% · Dementia 5%.

The office billed $198,666, Medicare allowed $47,742 and paid $36,530; for 1,365 services of 20 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243761,365711.31$198,666$36,530
20233591,272711.44$187,720$36,162
20224511,419701.32$212,350$39,846
20213801,351701.60$215,598$44,811
20203351,333701.57$193,602$41,914
20193611,260691.91$196,756$42,801
20184151,367681.83$213,084$46,521
20174211,415691.93$225,452$46,015
20163831,248672.11$210,893$44,421
20153501,148672.24$180,567$33,349
20144231,253682.14$221,361$37,311
20133181,042682.13$184,178$35,687

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 9 services

Original Medicare services billed in 2023
Pathology examination of tissue using a microscope, intermediate complexity296$17,004$27
Special stained specimen slides to examine tissue, each additional procedure64$5,388$22
Special stained specimen slides to examine tissue, initial procedure110$3,772$27
Pathology examination of tissue using a microscope, high complexity13$3,198$110
Pathology examination of tissue using a microscope, moderately high complexity25$2,101$62
Microscopic genetic analysis of tumor, manual24$1,146$32
Pathology examination of specimen during surgery, first tissue block14$945$47
Special stained specimen slides to identify organisms including interpretation and report16$486$20
Pathology examination of tissue using a microscope, moderately low complexity29$294$9

2022: 12 services

Original Medicare services billed in 2022
Pathology examination of tissue using a microscope, intermediate complexity367$20,034$25
Special stained specimen slides to examine tissue, each additional procedure59$4,887$21
Special stained specimen slides to examine tissue, initial procedure124$4,082$26
Pathology examination of tissue using a microscope, high complexity20$3,443$108
Pathology examination of tissue using a microscope, moderately high complexity33$2,919$63
Surgical pathology consultation and report on referred material requiring preparation of slides11$757$69
Microscopic genetic analysis of tumor, manual15$688$33
Surgical pathology consultation and report on referred slides prepared elsewhere11$596$54
Special stained specimen slides to identify organisms including interpretation and report16$541$21
Special stained specimen slides to examine tissue including interpretation and report14$242$9
Pathology examination of tissue using a microscope, moderately low complexity19$224$9
Pathology examination of tissue using a microscope13$66$5

2021: 12 services

Original Medicare services billed in 2021
Pathology examination of tissue using a microscope, intermediate complexity289$16,922$29
Pathology examination of tissue using a microscope, high complexity24$6,522$114
Special stained specimen slides to examine tissue, each additional procedure56$6,032$23
Pathology examination of tissue using a microscope, moderately high complexity49$5,295$65
Special stained specimen slides to examine tissue, initial procedure113$3,699$27
Pathology examination of specimen during surgery, first tissue block21$1,582$49
Microscopic genetic analysis of tumor, manual23$1,005$34
Surgical pathology consultation and report on referred material requiring preparation of slides14$905$65
Surgical pathology consultation and report on referred slides prepared elsewhere12$805$67
Special stained specimen slides to identify organisms including interpretation and report14$490$20
Pathology examination of tissue using a microscope, moderately low complexity38$465$9
Special stained specimen slides to examine tissue including interpretation and report11$281$10

2020: 10 services

Original Medicare services billed in 2020
Pathology examination of tissue using a microscope, intermediate complexity252$15,059$29
Special stained specimen slides to examine tissue, each additional procedure64$8,828$23
Pathology examination of tissue using a microscope, moderately high complexity45$4,720$68
Pathology examination of tissue using a microscope, high complexity18$4,592$121
Special stained specimen slides to examine tissue, initial procedure120$4,219$29
Surgical pathology consultation and report on referred material requiring preparation of slides11$796$72
Special stained specimen slides to identify organisms including interpretation and report16$571$22
Microscopic genetic analysis of tumor, manual13$524$35
Pathology examination of tissue using a microscope, moderately low complexity33$406$9
Special stained specimen slides to examine tissue including interpretation and report17$350$10

2019: 14 services

Original Medicare services billed in 2019
Pathology examination of tissue using a microscope, intermediate complexity268$15,997$30
Special stained specimen slides to examine tissue, each additional procedure61$6,763$23
Pathology examination of tissue using a microscope, high complexity24$5,770$118
Special stained specimen slides to examine tissue, initial procedure124$4,188$29
Pathology examination of tissue using a microscope, moderately high complexity30$3,804$68
Pathology examination of specimen during surgery, first tissue block14$1,128$51
Surgical pathology consultation and report on referred material requiring preparation of slides13$931$72
Surgical pathology consultation and report on referred slides prepared elsewhere12$821$68
Special stained specimen slides to identify organisms including interpretation and report24$609$22
Microscopic genetic analysis of tumor, manual12$417$35
Cell examination of specimen, selective cellular enhancement technique13$320$23
Pathology examination of tissue using a microscope, moderately low complexity26$317$9
Special stained specimen slides to examine tissue including interpretation and report11$158$10
Pathology examination of tissue using a microscope11$62$6

2018: 12 services

Original Medicare services billed in 2018
Pathology examination of tissue using a microscope, intermediate complexity296$17,709$30
Special stained specimen slides to examine tissue, each additional procedure69$6,751$23
Pathology examination of tissue using a microscope, high complexity24$5,982$120
Pathology examination of tissue using a microscope, moderately high complexity51$5,463$67
Special stained specimen slides to examine tissue, initial procedure123$4,060$29
Pathology examination of specimen during surgery, first tissue block17$1,533$51
Surgical pathology consultation and report on referred material requiring preparation of slides13$916$70
Surgical pathology consultation and report on referred slides prepared elsewhere13$795$61
Special stained specimen slides to identify organisms including interpretation and report15$540$22
Microscopic genetic analysis of tumor, manual14$503$36
Pathology examination of tissue using a microscope, moderately low complexity40$399$9
Special stained specimen slides to examine tissue including interpretation and report12$184$10

2017: 13 services

Original Medicare services billed in 2017
Pathology examination of tissue using a microscope, intermediate complexity322$16,935$27
Pathology examination of tissue using a microscope, high complexity22$6,550$119
Special stained specimen slides to examine tissue, each additional procedure73$6,320$23
Special stained specimen slides to examine tissue, initial procedure130$4,113$28
Pathology examination of tissue using a microscope, moderately high complexity30$3,640$67
Evaluation of fine needle aspirate with interpretation and report24$1,882$57
Surgical pathology consultation and report on referred material requiring preparation of slides15$975$65
Pathology examination of specimen during surgery, first tissue block14$962$51
Surgical pathology consultation and report on referred slides prepared elsewhere13$872$67
Special stained specimen slides to identify organisms including interpretation and report32$771$21
Cell examination of specimen, selective cellular enhancement technique30$760$22
Evaluation of fine needle aspirate13$438$29
Pathology examination of tissue using a microscope, moderately low complexity27$322$9

2016: 12 services

Original Medicare services billed in 2016
Pathology examination of tissue using a microscope, intermediate complexity262$15,081$29
Pathology examination of tissue using a microscope, high complexity25$8,403$118
Pathology examination of tissue using a microscope, moderately high complexity51$5,215$66
Special stained specimen slides to examine tissue, each additional procedure56$4,403$21
Special stained specimen slides to examine tissue, initial procedure99$3,234$28
Pathology examination of specimen during surgery, first tissue block23$1,555$50
Evaluation of fine needle aspirate with interpretation and report18$1,420$57
Surgical pathology consultation and report on referred slides prepared elsewhere21$1,336$64
Cell examination of specimen, selective cellular enhancement technique27$602$22
Special stained specimen slides to identify organisms including interpretation and report27$591$21
Pathology examination of tissue using a microscope, moderately low complexity33$308$9
Special stained specimen slides to examine tissue including interpretation and report13$231$10

2015: 11 services

Original Medicare services billed in 2015
Pathology examination of tissue using a microscope, intermediate complexity247$14,090$28
Special stained specimen slides to examine tissue, initial procedure95$3,113$27
Special stained specimen slides to examine tissue, each additional procedure48$3,018$16
Pathology examination of tissue using a microscope, high complexity13$2,791$116
Pathology examination of tissue using a microscope, moderately high complexity18$2,041$66
Evaluation of fine needle aspirate with interpretation and report30$1,989$54
Special stained specimen slides to identify organisms including interpretation and report52$1,297$21
Cell examination of specimen, selective cellular enhancement technique51$1,240$22
Surgical pathology consultation and report on referred slides prepared elsewhere14$932$67
Evaluation of fine needle aspirate11$457$29
Pathology examination of tissue using a microscope, moderately low complexity17$227$9

2014: 12 services

Original Medicare services billed in 2014
Pathology examination of tissue using a microscope, intermediate complexity284$15,430$29
Pathology examination of tissue using a microscope, high complexity24$6,277$114
Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain103$2,688$23
Pathology examination of tissue using a microscope, moderately high complexity25$2,256$64
Evaluation of fine needle aspirate with interpretation and report38$2,209$55
Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure)65$1,914$10
Cell examination of specimen, selective cellular enhancement technique59$1,453$22
Special stained specimen slides to identify organisms including interpretation and report50$1,280$21
Pathology examination of specimen during surgery, first tissue block13$959$48
Surgical pathology consultation and report on referred slides prepared elsewhere12$727$61
Evaluation of fine needle aspirate16$443$28
Pathology examination of tissue using a microscope, moderately low complexity35$352$9

2013: 10 services

Original Medicare services billed in 2013
Pathology examination of tissue using a microscope, intermediate complexity217$12,803$28
Special stained specimen slides to examine tissue, initial procedure79$8,773$32
Pathology examination of tissue using a microscope, high complexity14$3,023$112
Pathology examination of tissue using a microscope, moderately high complexity30$2,786$63
Cell examination of specimen, selective cellular enhancement technique29$1,428$45
Surgical pathology consultation and report on referred slides prepared elsewhere17$1,421$65
Evaluation of fine needle aspirate with interpretation and report23$1,403$52
Pathology examination of specimen during surgery, first tissue block16$1,268$45
Special stained specimen slides to identify organisms including interpretation and report37$1,039$20
Pathology examination of tissue using a microscope, moderately low complexity21$226$9

Medicaid work

$16,785 in 2024

Medicaid paid $16,785 for 249 billed services this clinician did in 2024, up to 46 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
TISSUE EXAM BY PATHOLOGIST236$16,408
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure13$377
Medicaid work by year
2024249246$16,785
2023238239$19,340
2022313240$25,714
2021176232$16,055
202037119$3,478
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
TISSUE EXAM BY PATHOLOGIST211$18,509
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure27$831

2022

Largest Medicaid services in 2022
TISSUE EXAM BY PATHOLOGIST256$24,080
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure57$1,634

2021

Largest Medicaid services in 2021
TISSUE EXAM BY PATHOLOGIST160$15,597
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure16$458

2020

Largest Medicaid services in 2020
TISSUE EXAM BY PATHOLOGIST37$3,478

Money from drug and device companies

$8,300 in 2025

Industry payments by year
202526$8,300$8,300
2024310$56,000$56,000
2023416$31,500$31,500
202226$26,900$26,900
202024$35,300$35,300
201914$5,400$5,400

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerVelsipity$7,200
5 payments
  • Consulting for Velsipity · 2025-08-18 · $1,500
  • Consulting for Velsipity · 2025-05-22 · $1,200
  • Consulting for Velsipity · 2025-05-22 · $1,500
  • Consulting for Velsipity · 2025-02-26 · $1,200
  • Consulting for Velsipity · 2025-02-26 · $1,800
Arena PharmaceuticalsVelsipity$1,100
1 payment
  • Consulting for Velsipity · 2025-11-12 · $1,100
See all 6 published payments
Every published payment
Arena PharmaceuticalsConsulting · 2025-11-12Velsipity$1,100
PfizerConsulting · 2025-08-18Velsipity$1,500
PfizerConsulting · 2025-05-22Velsipity$1,200
PfizerConsulting · 2025-05-22Velsipity$1,500
PfizerConsulting · 2025-02-26Velsipity$1,200
PfizerConsulting · 2025-02-26Velsipity$1,800
See earlier years (2024, 2023, 2022, 2020, 2019)

2024: $56,000

Payments by company in 2024
Arena PharmaceuticalsVelsipity$34,100
6 payments
  • Consulting for Velsipity · 2024-05-16 · $10,800
  • Consulting for Velsipity · 2024-05-16 · $3,900
  • Consulting for Velsipity · 2024-05-16 · $500
  • Consulting for Velsipity · 2024-02-16 · $13,200
  • Consulting for Velsipity · 2024-02-16 · $4,000
  • Consulting for Velsipity · 2024-02-16 · $1,700
MedivationVelsipity$12,600
3 payments
  • Consulting for Velsipity · 2024-08-15 · $5,100
  • Consulting for Velsipity · 2024-08-15 · $300
  • Consulting for Velsipity · 2024-08-15 · $7,200
AstraZeneca Pharmaceuticals LPNone$9,300
1 payment
  • Consulting · 2024-02-16 · $9,300

2023: $31,500

Payments by company in 2023
Arena PharmaceuticalsVelsipity$23,400
8 payments
  • Consulting for Velsipity · 2023-11-17 · $4,100
  • Consulting for Velsipity · 2023-11-17 · $4,100
  • Consulting for Velsipity · 2023-11-17 · $2,100
  • Consulting for Velsipity · 2023-08-15 · $3,900
  • Consulting for Velsipity · 2023-08-15 · $1,000
  • Consulting for Velsipity · 2023-05-02 · $600
  • Consulting for Velsipity · 2023-05-02 · $5,800
  • Consulting for Velsipity · 2023-05-02 · $1,800
PfizerLitfulo$3,600
4 payments
  • Consulting for Litfulo · 2023-11-17 · $900
  • Consulting for Litfulo · 2023-08-15 · $900
  • Consulting for Litfulo · 2023-05-02 · $1,500
  • Consulting for Litfulo · 2023-02-16 · $300
Boehringer Ingelheim RCV GmbH & Co KGSpevigo$3,600
2 payments
  • Consulting for Spevigo · 2023-08-15 · $2,700
  • Consulting for Spevigo · 2023-02-16 · $900
AstraZeneca Pharmaceuticals LPNone$900
2 payments
  • Consulting · 2023-08-15 · $300
  • Consulting · 2023-08-15 · $600

2022: $26,900

Payments by company in 2022
PfizerNone$23,400
4 payments
  • Consulting · 2022-11-07 · $4,200
  • Consulting · 2022-08-04 · $9,900
  • Consulting · 2022-05-05 · $8,700
  • Consulting · 2022-01-28 · $600
Boehringer Ingelheim RCV GmbH & Co KGSpevigo$3,500
2 payments
  • Consulting for Spevigo · 2022-07-11 · $300
  • Consulting · 2022-01-28 · $3,200

2020: $35,300

Payments by company in 2020
PfizerNone$33,000
3 payments
  • Consulting · 2020-11-05 · $14,100
  • Consulting · 2020-09-30 · $14,100
  • Consulting · 2020-06-30 · $4,800
Boehringer Ingelheim RCV GmbH & Co KGPipeline$2,300
1 payment
  • Paid to speak or teach for Pipeline · 2020-04-21 · $2,300

2019: $5,400

Payments by company in 2019
PfizerNone$5,400
4 payments
  • Consulting · 2019-10-23 · $400
  • Consulting · 2019-07-22 · $600
  • Consulting · 2019-07-22 · $3,400
  • Consulting · 2019-04-30 · $1,000

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
AbbVie Inc. · Rinvoq · 2020This clinician$57,200
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2021This clinician$43,100
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2020This clinician$39,800
ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2022This clinician$36,800
Celltrion, Inc. · 2022This clinician$35,600
Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2022This clinician$30,300
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2021This clinician$26,500
Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2024This clinician$26,100
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study To Evaluate the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021This clinician$25,300
Eli Lilly and Company · A Phase 3 Multicenter Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2023This clinician$18,000
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Upadacitinib (Abt-494) for Induction and Maintenance Therapy in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021This clinician$16,500
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Moderately To Severely Active Crohns Disease Who Have Inadequately Responded To Or Are Intolerant To Biologic Therapy · 2021This clinician$15,900
AbbVie, Inc. · 2019This clinician$14,200
AbbVie Inc. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2023This clinician$14,200
AbbVie Inc. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately To Severely Active Ulcerative Colitis · 2023This clinician$13,100
AbbVie, Inc. · Rinvoq · 2019This clinician$12,900
ABBVIE INC. · A Study of the Efficacy and Safety of Upadacitnib (Abt-494) in Participants With Moderately To Severely Active Crohns Disease Who Have Inadequately Responded To Or Are Intolerant To Conventional and/Or Biologic Therapies · 2022This clinician$12,900
Takeda Pharmaceuticals U.S.A., Inc. · In Active Ulcerative Colitis, A Randomized Controlled Trial for Determination of the Optimal Treatment Target · 2023Their institution$12,740
AbbVie Inc. · Skyrizi · 2020This clinician$11,400
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2022This clinician$9,800
ABBVIE INC. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2022This clinician$9,300
ABBVIE INC. · A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease · 2022This clinician$9,000
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study To Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021This clinician$8,300
Takeda Pharmaceuticals U.S.A., Inc. · Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab To Other Biologic Agents in Patients With Ulcerative Colitis Or Crohn'S Disease · 2023Their institution$8,120
Celltrion, Inc. · 2023This clinician$7,700
Takeda Pharmaceuticals U.S.A., Inc. · In Active Ulcerative Colitis, A Randomized Controlled Trial for Determination of the Optimal Treatment Target · 2024Their institution$7,700
Takeda Pharmaceuticals U.S.A., Inc. · In Active Ulcerative Colitis, A Randomized Controlled Trial for Determination of the Optimal Treatment Target · 2022Their institution$6,930
AbbVie Inc. · A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Participants With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2023This clinician$6,600
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study To Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately To Severely Active Crohns Disease Who Failed Prior Biologic Treatment · 2021This clinician$6,300
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2024This clinician$6,000
Eli Lilly and Company · An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of Ly3471851 (Nktr 358) in Patients With Moderately To Severely Active Ulcerative Colitis · 2022This clinician$5,900
Takeda Pharmaceuticals U.S.A., Inc. · A Double Blind, Randomized, Placebo Controlled, Parallel Group Study To Simultaneosly Qualify A Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due To Alzheimer'S Disease (Mci Due To Ad) and To Test the Safety and Efficacy of Pioglitazone (Ad-4833 Sr 0.8 Mg Qd) To Delay the Onset of Mci Due To Ad in Cognitively Normal Subjects · 2025This clinician$5,610
Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2025This clinician$5,500
ABBVIE INC. · A Study To Evaluate the Safety and Efficacy of Upadacitinib (Abt-494) for Induction and Maintenance Therapy in Participants With Moderately To Severely Active Ulcerative Colitis (UC) · 2022This clinician$5,000
ABBVIE INC. · A Study To Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis · 2024This clinician$4,900
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Moderately To Severely Active Crohns Disease Who Have Inadequately Responded To Or Are Intolerant To Conventional and/Or Biologic Therapies · 2021This clinician$4,800
Takeda Pharmaceuticals U.S.A., Inc. · Verdict · 2025This clinician$4,550
Takeda Pharmaceuticals U.S.A., Inc. · Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab To Other Biologic Agents in Patients With Ulcerative Colitis Or Crohn'S Disease · 2025This clinician$3,360
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (Abt-494) in Subjects With Crohns Disease Who Completed the Studies M14-431 Or M14-433 · 2021This clinician$3,300
Takeda Pharmaceuticals U.S.A., Inc. · Tak-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study To Evaluate the Efficacy and Safety of Oral Tak-279 in Subjects With Moderately To Severely Active Ulcerative Colitis · 2025This clinician$2,970
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1, Open-Label, Randomized Parallel Group Study To Assess the Pharmacokinetics of Single Intravenous and Subcutaneous Injections of Vedolizumab Administered in Healthy Subjects · 2024Their institution$2,870
ABBVIE INC. · A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately To Severely Active Ulcerative Colitis · 2021This clinician$2,400
Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2020This clinician$2,300
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2020This clinician$2,300
Eli Lilly and Company · A Phase 3 Multicenter Randomized Double-Blind Parallel Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2023This clinician$2,200
ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and An Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis · 2021This clinician$2,200
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2024This clinician$1,800
Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2025This clinician$1,800
Eli Lilly and Company · A Phase 3 Multicenter Randomized Double-Blind Parallel-Arm Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2023This clinician$300

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
77.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1962608364
Licence
CA A89127California A89127: Cancelled
Trained
University of New Mexico School of Medicine, 2001
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207ZP0102X (207ZP0102X)
Mailing address
300 Pasteur Dr, Room A608, Stanford, CA, 94305
NPI first listed
2007-06-22
NPI last updated
2021-05-24

This is when the NPI record was last certified, not a medical board exam.

This office lists an electronic records connection.